Transcode interim CFO reports no RNAZ holdings

Interim CFO John A. Tattory filed an initial Form 3 for Transcode Therapeutics with no reportable holdings or trades.

Available on EDGAR 09/21/2026 - 05:42 PM EDT Accepted by SEC EDGAR 09/21/2026 - 05:42 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Transcode Therapeutics, Inc. (RNAZ) has an initial insider ownership report on file for John A. Tattory, who serves as Interim CFO. The Form 3 lists him as an officer but shows no reportable holdings or transactions in Transcode Therapeutics securities at the time of filing. The filing also references an Exhibit 24 Power of Attorney related to this reporting.

Key Figures

Buy transactions: 0 transactions Sell transactions: 0 transactions Net buy/sell shares: 0 shares +1 more

4 metrics

Buy transactions 0 transactions Count of reported purchase transactions on this Form 3

Sell transactions 0 transactions Count of reported sale transactions on this Form 3

Net buy/sell shares 0 shares Net shares bought or sold as summarized in the filing

Holding entries 0 holdings Number of reportable positions in issuer securities

Key Terms

Form 3, beneficial ownership, Power of Attorney, Interim CFO

4 terms

Form 3 regulatory

"has an initial insider ownership report on file for John A. Tattory"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

beneficial ownership financial

"initial statement of beneficial ownership for the Interim CFO"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Power of Attorney regulatory

"The filing also references an Exhibit 24 Power of Attorney"

A power of attorney is a legal document that allows one person to make decisions and act on behalf of another person, often in financial or legal matters. It’s like giving someone a trusted helper or agent the authority to handle important tasks if you are unable to do so yourself. This matters to investors because it can impact how their assets are managed or transferred if they become unable to oversee their affairs.

Interim CFO financial

"lists him as an officer but shows no reportable holdings"

An interim CFO is a temporary chief financial officer hired to run a company’s finance operations during a leadership transition, a search for a permanent hire, or while specific financial issues are resolved. Investors pay attention because this person manages budgeting, financial reporting and communications with shareholders—like a substitute driver keeping a car on course—so their competence affects short‑term financial stability, the accuracy of public reports, and market confidence.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 3 filing by the Interim CFO mean for Transcode Therapeutics (RNAZ)?

The Form 3 records that John A. Tattory, the Interim CFO, is now a reporting officer of Transcode Therapeutics. At the time of this filing, it shows no reportable holdings or transactions in the company’s securities.

Did the Interim CFO report any share ownership of RNAZ on this Form 3?

No. The Form 3 for Transcode Therapeutics’ Interim CFO reports no holdings entries, meaning no reportable beneficial ownership of company securities is listed as of the filing.

Are there any buy or sell transactions for RNAZ reported in this Form 3?

No. The transaction summary shows 0 buy transactions, 0 sell transactions, and 0 net buy/sell shares, indicating no trades are reported in this initial statement.

Does the Form 3 for RNAZ mention a Rule 10b5-1 trading plan?

No. The document-level Rule 10b5-1 indicator is null, and there are no transactions or footnotes describing any trading plan in this Form 3.

What additional document is referenced in the RNAZ Form 3 remarks?

The remarks section references Exhibit 24: Power of Attorney, indicating a Power of Attorney has been filed in connection with this reporting, authorizing the signing or submission of ownership reports.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Tattory John A

(Last) (First) (Middle)

C/O TRANSCODE THERAPEUTICS, INC.

6 LIBERTY SQUARE, #2382

(Street)

BOSTON MASSACHUSETTS 02109

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
09/10/2026

3. Issuer Name and Ticker or Trading Symbol
Transcode Therapeutics, Inc. [ RNAZ ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Interim CFO

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24: Power of Attorney

No securities are beneficially owned.

	/s/ Philippe P. Calais, Attorney-in-Fact	09/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)